Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 28, 2005; 11(44): 6988-6994
Published online Nov 28, 2005. doi: 10.3748/wjg.v11.i44.6988
Table 1 Baseline characteristics of the study populations tested for anti-Saccharomyces cerevisiae IgG and IgA antibodies. Unless otherwise indicated values are numbers of patients (%)
Study populationCrohn’s disease (n = 66)Ulcerative colitis (n = 29)Healthy controls (n = 18)IBS patients (n = 10)
Age, yr
Mean±SD38±1637±1540±1357±13
Range14-8216-7817-7441-81
Male sex32 (48)15 (52)10 (56)6 (60)
Disease location
Colonic58 (88)29 (100)
Ileal45 (68)
Upper gastrointestinal involvement3 (5)
Presence of fistulae15 (23)1 (3)
Extraintestinal manifestations4 (6)0 (0)
Medical therapy
Azathioprine22 (33)9 (31)
Infliximab5 (8)3 (10)
5-ASA compounds4 (6)11 (38)
Methotrexate4 (6)0 (0)
Oral steroids29 (44)15 (52)
None of the above19 (29)7 (24)
Table 2 Mean, standard deviation (SD) and the 95% confidence interval of the mean of the change in ASCA IgG and IgA titers
IgGIgA
MeanSD95%CIMeanSD95%CI
CD0.010.56(-0.20, 0.22)-0.040.25(-0.13, 0.05)
UC0.050.15(-0.03, 0.14)0.160.24(0.02, 0.29)
IBS0.050.08(-0.003, 0.09)-0.010.12(-0.08, 0.06)
Table 3 Effect of the CD clinical characteristics on the following parameters: ASCA IgG and IgA positivity and change in IgG and IgA ASCA titers. Results are expressed as P-values of the mean-difference tests or as correlation coefficients (c)
Clinical characteristicsASCA IgGASCA IgA∆IgG∆IgA
Correlation with agec = –0.140c = 0.198c = –0.340c = –0.197
Male vs female0.8810.8810.0890.571
Disease Location
Colonic vs non-colonic0.6670.1690.2030.289
Ileal vs non-ileal0.2850.2850.032a0.395
Fistular vs Non-fistular disease0.1520.0750.4990.907
Medical therapy
Azathioprine0.8810.8810.7490.375
Infliximab0.2330.2330.870.844
5-ASA compounds0.8060.2330.9030.491
Oral steroids0.5120.3850.4750.531
None of the above medical
therapy vs medical therapy0.2850.5770.4380.117